[1]
Reich, K., Simpson, E.L., Langley, R., Warren, R.B., Costanzo, A., Saeki, H., Almgren, P., Gjerum, L., Carlsson, A., Gooderham, M., Pinter, A., de Bruin-Weller, M. and Blauvelt, A. 2022. Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s79. DOI:https://doi.org/10.25251/skin.6.supp.79.